Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

A Case of Multiple Sclerosis with Protracted Course of COVID-19

Author(s): Mehrdad Hasibi*, Marjan Asadollahi and Ali Asadollahi-Amin

Volume 22, Issue 4, 2022

Published on: 15 March, 2022

Article ID: e280122200652 Pages: 3

DOI: 10.2174/1871526522666220128121855

Price: $65

Abstract

Background: We reported a case of multiple sclerosis (MS) with persistent symptomatic COVID-19, which was complicated by new-appearing severe pneumonia 40 days after disease onset.

Case Presentation: A 38-year-old man with a history of multiple sclerosis referred to our hospital with fever, shaking chills, cough, and dyspnea. In his history, the patient had developed mild COVID-19 from 40 days ago. After 7 days of disease onset, the COVID symptoms had been subsided partially, but fatigue, myalgia, intermittent fever, and loss of taste and smell had been continued. In physical examinations, his oral temperature was 39.4 °C. He had respiratory distress, and his blood oxygen saturation on the room air was 90%. The spiral chest CT scan was performed, which revealed bilateral ground-glass and alveolar opacities in favor of COVID-19 pneumonia. The result of the RT-PCR test for SARS-COV-2 was reported positive subsequently. His current MS medication was rituximab and he had received the last dose of rituximab two months before developing COVID-19. The patient was admitted to the COVID ward and put on Remdesivir, subcutaneous interferon-beta1b, and dexamethasone. He improved gradually and was discharged from the hospital with the favorable condition after 10 days. This patient had a rare protracted disease course. We presumed that prolonged high degree fever (above 38 °C) in our patient is beyond the diagnosis of the post-COVID-19 syndrome and is more compatible with persistent infection.

Conclusion: Although most immunocompromised patients effectively clear SARS-CoV-2 infection, this case report highlights the risk of persistent infection associated with recurrence of the disease.

Keywords: Immunocompromised patients, rituximab, post-COVID syndrome, persistent infection, respiratory distress, infection.

[1]
Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020; 324(17): 1723-4.
[http://dx.doi.org/10.1001/jama.2020.19719] [PMID: 33031513]
[2]
Assaf G, Davis H, McCorkell L, et al. What does COVID-19 recovery actually look like? An analysis of the prolonged COVID-19 symptoms survey by Patient-Led Research Team. Patient Led Research for COVID-19 2020.
[3]
Banda JM, Singh GV, Alser O, et al. Long-term patient-reported symptoms of COVID-19: An analysis of social media data. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.29.20164418]
[4]
O’Keefe JB, Cellai M. Characterization of prolonged COVID-19 symptoms and patient comorbidities in an outpatient telemedicine cohort. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.05.20146886]
[5]
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603-5.
[http://dx.doi.org/10.1001/jama.2020.12603] [PMID: 32644129]
[6]
Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res 2020; 6(4): 00542-2020.
[http://dx.doi.org/10.1183/23120541.00542-2020] [PMID: 33257910]
[7]
He X, Lau EH, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26: 672-5.
[http://dx.doi.org/10.1038/s41591-020-0869-5]
[8]
Wei L, Liu B, Zhao Y, Chen Z. Prolonged shedding of SARS-COV-2 in an elderly liver transplant patient infected by COVID-19: A case report. Ann Palliat Med 2021; 10(6): 7003-7.
[http://dx.doi.org/10.21037/apm-20-996] [PMID: 33183020]
[9]
Avanzato VA, Matson MJ, Seifert SN, et al. Case study: Prolonged infectious SARS-COV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020; 183(7): 1901-1912.e9.
[http://dx.doi.org/10.1016/j.cell.2020.10.049] [PMID: 33248470]
[10]
Lakhani HV, Pillai SS, Zehra M, Sharma I, Sodhi K. Systematic review of clinical insights into novel coronavirus (CoVID-19) pandemic: Persisting challenges in U.S. rural population. Int J Environ Res Public Health 2020; 17(12): 4279.
[http://dx.doi.org/10.3390/ijerph17124279] [PMID: 32549334]
[11]
Aydillo Teresa, Ana S. Gonzalez‐Reiche, Sadaf Aslam, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383(26): 2586-8.
[http://dx.doi.org/10.1056/NEJMc2031670] [PMID: 33259154]
[12]
Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020; 13(1): 131.
[http://dx.doi.org/10.1186/s13045-020-00968-1] [PMID: 33008453]
[13]
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J Intensive Care 2020; 8: 36.
[http://dx.doi.org/10.1186/s40560-020-00453-4] [PMID: 32483488]
[14]
Jason J. Emer, Wolinsky Claire. 6.Rituximab: A review of dermatological applications. Clin Aesthet Dermatol 2009; 2(5): 29-37.
[PMID: 20729962]
[15]
Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int 2020; 40(12): 2117-8.
[http://dx.doi.org/10.1007/s00296-020-04715-0] [PMID: 33044704]
[16]
Schulze-Koops H, Krueger K, Vallbracht I, et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020; 80(5): e68.
[http://dx.doi.org/10.1136/annrheumdis-2020-218075] [PMID: 32591357]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy